ATE353954T1 - Immuntherapie für krebs - Google Patents

Immuntherapie für krebs

Info

Publication number
ATE353954T1
ATE353954T1 AT02022787T AT02022787T ATE353954T1 AT E353954 T1 ATE353954 T1 AT E353954T1 AT 02022787 T AT02022787 T AT 02022787T AT 02022787 T AT02022787 T AT 02022787T AT E353954 T1 ATE353954 T1 AT E353954T1
Authority
AT
Austria
Prior art keywords
lymphocytes
sentinel
dukes
nodes
proliferation
Prior art date
Application number
AT02022787T
Other languages
English (en)
Inventor
Ola Winqvist
Magnus Thoern
Original Assignee
Sentoclone Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentoclone Therapeutics Ab filed Critical Sentoclone Therapeutics Ab
Application granted granted Critical
Publication of ATE353954T1 publication Critical patent/ATE353954T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0651—Lymph nodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02022787T 2002-10-11 2002-10-11 Immuntherapie für krebs ATE353954T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022787A EP1408106B1 (de) 2002-10-11 2002-10-11 Immuntherapie für Krebs

Publications (1)

Publication Number Publication Date
ATE353954T1 true ATE353954T1 (de) 2007-03-15

Family

ID=32010966

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02022787T ATE353954T1 (de) 2002-10-11 2002-10-11 Immuntherapie für krebs

Country Status (12)

Country Link
US (1) US8709404B2 (de)
EP (2) EP1808200A3 (de)
JP (2) JP5652984B2 (de)
AT (1) ATE353954T1 (de)
AU (1) AU2003269760B2 (de)
CY (1) CY1106573T1 (de)
DE (1) DE60218173T2 (de)
DK (1) DK1408106T3 (de)
ES (1) ES2282355T3 (de)
NZ (1) NZ539843A (de)
PT (1) PT1408106E (de)
WO (1) WO2004032951A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE353954T1 (de) 2002-10-11 2007-03-15 Sentoclone Therapeutics Ab Immuntherapie für krebs
EP1444989A1 (de) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
US20050249699A1 (en) * 2004-05-05 2005-11-10 Stoff Jesse A Immunodynamic complexes and methods for using and preparing such complexes
SG165328A1 (en) * 2005-08-31 2010-10-28 Ith Immune Therapy Holdings Ab Treatment of inflammatory bowel disease
US8211425B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
WO2007071410A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating urinary bladder cancer
US8007785B2 (en) 2005-12-21 2011-08-30 Sentoclone International Ab Method for treating colon cancer with tumour-reactive T-lymphocytes
AU2006328945B2 (en) * 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
CA2634167C (en) * 2005-12-21 2015-06-16 Sentoclone Ab Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
US7951365B2 (en) * 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
EP3156069B8 (de) 2008-06-20 2020-10-21 Duke University Zusammensetzungen, verfahren und kits zur auslösung einer immunreaktion
JP2011528326A (ja) * 2008-07-18 2011-11-17 セントクローネ インターナショナル エービー インビトロ拡大されたｔリンパ球及びガン治療に適切な血管形成インヒビターを含む組成物
EP2375897A4 (de) * 2009-01-14 2013-05-15 Health Research Inc Verfahren und zusammensetzungen mit mtor-hemmern zur verstärkung von immunreaktionen
CN110878282A (zh) * 2019-05-09 2020-03-13 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种肿瘤抗原特异性t淋巴细胞的制备方法
AU2022337186A1 (en) 2021-08-30 2025-03-06 Carrygenes Bioengineering, Llc Use of chemokine receptors in cellular homing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311688A (en) 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
JPH05502369A (ja) * 1989-09-14 1993-04-28 セルコ、インコーポレイテッド 養子免疫療法に用いられる生体外増殖リンパ性細胞の製造方法
US5814295A (en) 1992-04-10 1998-09-29 The Ohio State University Research Foundation Determination of lymph nodes enriched in tumor reactive cells their proliferation and their use in adoptive cellular therapy
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
ES2278390T3 (es) * 1996-05-23 2007-08-01 The Scripps Research Institute Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+.
WO1999053949A2 (en) 1998-04-23 1999-10-28 Arch Development Corporation Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy
AU4603499A (en) 1998-06-26 2000-01-17 Joergen Agnholt Methods of expanding and selecting disease associated t-cells
AU5905400A (en) * 1999-07-14 2001-02-05 Board Of Regents, The University Of Texas System Methods and compositions for delivery and retention of active agents to lymph nodes
GB0007088D0 (en) 2000-03-23 2000-05-17 Torsana A S Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
US20030228635A1 (en) * 2002-02-15 2003-12-11 Renovar, Inc. Cell proliferation assays and methods
CA2492938C (en) 2002-08-02 2012-05-22 Joseph H. Coggin, Jr. Cancer vaccines containing epitopes of oncofetal antigen
US7897336B2 (en) 2002-08-16 2011-03-01 John Wayne Cancer Institute Molecular lymphatic mapping of sentinel lymph nodes
ATE353954T1 (de) 2002-10-11 2007-03-15 Sentoclone Therapeutics Ab Immuntherapie für krebs
EP1561819A4 (de) 2002-10-24 2006-03-22 Dnavec Research Inc Verfahren zur übertragung eines gens in t-zellen
EP1419787A1 (de) 2002-11-18 2004-05-19 Uwe Prof. Dr. Till Lymphknoten-Kontrastmittel
WO2007071410A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating urinary bladder cancer
US8007785B2 (en) 2005-12-21 2011-08-30 Sentoclone International Ab Method for treating colon cancer with tumour-reactive T-lymphocytes
US8211425B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
AU2006328945B2 (en) 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
CA2634167C (en) 2005-12-21 2015-06-16 Sentoclone Ab Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
US7951365B2 (en) 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
JP2011528326A (ja) 2008-07-18 2011-11-17 セントクローネ インターナショナル エービー インビトロ拡大されたｔリンパ球及びガン治療に適切な血管形成インヒビターを含む組成物

Also Published As

Publication number Publication date
EP1408106A1 (de) 2004-04-14
US20070141026A1 (en) 2007-06-21
WO2004032951A1 (en) 2004-04-22
EP1808200A3 (de) 2007-09-19
CY1106573T1 (el) 2012-01-25
US8709404B2 (en) 2014-04-29
PT1408106E (pt) 2007-04-30
JP2012197260A (ja) 2012-10-18
DE60218173D1 (de) 2007-03-29
JP5946282B2 (ja) 2016-07-06
DE60218173T2 (de) 2007-11-22
EP1808200A2 (de) 2007-07-18
AU2003269760B2 (en) 2008-08-28
EP1408106B1 (de) 2007-02-14
AU2003269760A1 (en) 2004-05-04
ES2282355T3 (es) 2007-10-16
JP2006507262A (ja) 2006-03-02
NZ539843A (en) 2008-05-30
JP5652984B2 (ja) 2015-01-14
DK1408106T3 (da) 2007-06-11

Similar Documents

Publication Publication Date Title
DE60218173D1 (de) Immuntherapie für Krebs
de Bruin et al. Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization
Badalamenti et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Chott et al. Most CD56+ intestinal lymphomas are CD8+ CD5− T-cell lymphomas of monomorphic small to medium size histology
Bouzidi et al. Prognostic value of natural killer cells besides tumor-infiltrating lymphocytes in breast cancer tissues
Caligaris-Cappio Review Role of the microenvironment in chronic lymphocytic leukaemia.
Platonova et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma
Shang et al. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients
Heeg et al. Insights into phenotypic and functional CD8+ TRM heterogeneity
Hasegawa et al. Epithelioid angiosarcoma of bone
WO2007071389A1 (en) Method for treating disseminated cancer
Kim et al. Metastatic colon cancer cell populations contain more cancer stem‑like cells with a higher susceptibility to natural killer cell‑mediated lysis compared with primary colon cancer cells
Redondo et al. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis
Moers et al. Regulation of CD95 (APO‐1/FAS) ligand and receptor expression in squamous‐cell carcinoma by interferon‐γ and cisplatin
Tremante et al. A melanoma immune response signature including Human Leukocyte Antigen‐E
Baba et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B
Ikeda et al. Multiple malignant melanoma and squamous-cell carcinoma in a burn scar
Darwish et al. Prognostic significance of CD24 expression in gastric carcinoma
Mannweiler et al. Colliding/concomitant tumors of the intestine: report of 3 cases
Homma et al. Human leukocyte antigen class I down‐regulation in muscle‐invasive bladder cancer: its association with clinical characteristics and survival after cystectomy
Berti et al. Primary anaplastic large cell lymphoma of the skin
Tsuneyama et al. Expression of MAGE‐A3 in intrahepatic cholangiocarcinoma and its precursor lesions
Osanto et al. Downmodulation of c-myc expression by interferon γ and tumour necrosis factor α precedes growth arrest in human melanoma cells
Ogoshi et al. HLA antigens are candidate markers for prediction of lymph node metastasis in gastric cancer
Russell et al. USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification

Ref document number: 1408106

Country of ref document: EP

EEIH Change in the person of patent owner